unknown by Cascini, Lucio Giuseppe et al.
35
Nuclear Medicine Review 2013, 16, 1: 35–41
10.5603/NMR.2012.0002





Signs or symptoms of impaired autonomic regulation of circu-
lation are typically present in patients affected by Parkinson’s 
disease (PD), in agreement with the cardiac sympathetic 
denervation discovered by Goldstein more than 15 yrs. ago. 
In particular, the majority of PD patients have a diffuse left ven-
tricular myocardial sympathetic denervation, being a normal 
neurological condition present only in a small number of af-
fected subjects. Actually MIBG cardiac imaging is a universally 
accepted method to estimate cardiac sympathetic innervations. 
This review covers the role of MIBG cardiac imaging in PD as well 
as in other parkinsonisms, focusing the attention on technical 
problems and pathophysiological premises for cardiac denerva-
tion. In particular new emerging data support the role of MIBG as 
biomarker of PD, also before motor symptoms became clinically 
evident. Therefore the timing of cardiac noradrenergic denerva-
tion in PD is a key issue and we want to update the analysis of 
autonomic cardiovascular abnormalities studied with MIBG in 
PD and related disorders.
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MIBG and the role of sympathetic  
cardiac innervations
Cardiac sympathetic innervation is responsible for hemody-
namic adaptations of the cardiovascular system to changing de-
mands. Nor-epinephrine (NE), neurotransmitter of the sympathetic 
system, is synthesized from the aminoacid tyrosine that is stored 
in high concentration in synaptic vesicles.
When a stimulus occurs, vesicles containing NE are released 
into the synaptic space, and NE bind to post synaptic beta-1, 
beta-2, and alfa receptors, enhancing adenyl-cyclase activity 
through an intermediary G protein, finally resulting in the cardiac 
stimulatory effects.
NE is taken back into the presynaptic terminal by a protein-me-
diated sodium energy and temperature-dependent transporter 
for storage or catabolic disposal that terminates the sympathetic 
response; this specific process of action is known as “uptake-1 
pathway”. Moreover part of NE into the synaptic space, is taken 
up by non-neuronal postsynaptic cells, probably through a passive 
diffusion (uptake-2 pathway) [1, 2].
Guanethidine, a false neurotransmitter analog of NE, may be 
chemically modified in meta-Iodo Benzyl Guanidine (mIBG) that 
can be labeled with radioactive iodine (123Iodine most commonly), 
becoming 123I-mIBG. mIBG is actively taken up through the uptake-1 
pathway by the postganglionic pre synaptic nerves endings of 
the adrenergic nervous system. In contrast to NE,123I-mIBG is not 
catabolized by monoamine oxidase or catechol-O-methyltrans-
ferase; therefore 123I-mIBG is retained and localized in myocar-
dial sympathetic nerve endings at a sufficient concentration to 
be imaged with a conventional gamma camera. On the basis of 
this pathophysiological premise, 123I-MIBG myocardial scintigraphy 
can non-invasively assess the postganglionic presynaptic cardiac 
sympathetic nerve endings.
Technical considerations  
for cardiac MIBG imaging
123I-mIBG injection is performed at rest and requires only 
a minimal preparation. Many medications, such as antidepressants, 
antipsychotics, and some calcium channel blockers, potentially 
interfere with catecholamine uptake and should be stopped at least 
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24 hours before radiotracer’s injection. A list of medications interfer-
ing with MIBG uptake is available at:
www.eanm.org/publications/guidelines/gloncomibg.pdf
After intravenous injection of 123I-mIBG, planar and single 
photon emission computed tomography (SPECT) images of the 
chest are obtained using a gamma camera at 15 min (early imag-
ing phase) and 3/4 hrs post-injection (delayed imaging phase). 
Cardiac MIBG uptake in the early imaging phase mainly re-
flects the density of the presynaptic cardiac sympathetic nerve 
endings, whereas the delayed imaging phase reflects the presyn-
aptic functional tone of the cardiac sympathetic nerve as well. The 
uptake can be semi-quantitatively evaluated by calculating the 
heart-to mediastinum (H/M) ratio by setting regions of interest over 
the heart and the upper mediastinum chosen on the anterior planar 
view of the chest as background.
The appropriate dosage of 123I-mIBG has not yet been defini-
tively established. In several published studies investigators have 
proposed a dose of 3–5 mCi, and this is generally satisfactory for 
a standard planar image analysis. Nevertheless , because it is often 
difficult to obtain satisfactory SPECT images using this dosage, 
particularly in patients with severe cardiac dysfunction or with 
severe neurological impairment, higher doses allowing a reduced 
time of acquisition and/or a better count rate may be appropriate.
Although some investigators suggest that only the delayed 
image should be used for interpretation and analysis because it rep-
resents actual neuronal uptake (as opposed to interstitial uptake in 
the early images), studies from other authors have reported that the 
estimation of mIBG washout rate (WR) between early and delayed 
images may provide additional information. In non-collaborative pa-
tients the early and delayed planar acquisitions with the estimation 
of WR may be considered a reasonable approach. This assumption 
is particularly true in patients with neurological impairment where 
motion artifacts may significantly affect image quality in SPECT, 
even more if myocardial uptake is reduced. In fact, global cardiac 
uptake as well as the estimation of the heart/mediastinal ratio 
(H/M) can be reliably assessed from planar images although the 
superposition of liver and lungs presenting high 123I-mIBG concen-
trations negatively affects scintigraphic acquisitions mainly in most 
seriously affected patients.
In the standard procedure, the H/M is calculated on a delayed 
anterior chest planar image by drawing a region of interest (ROI) 
including the heart (H) and the other one over the upper me-
diastinum; the mean counts per pixel in the heart are divided by the 
mean counts per pixel in the mediastinum. The method proposed 
by various investigators in defining the cardiac ROI are different, 
with some authors using a ROI limited to the myocardial wall, 
others drawing a ROI around the entire heart, and still others draw-
ing the ROI around the entire heart, but excluding the cavity. In the 
neurological setting we prefer to draw the ROI around the entire 
heart because in these patients a markedly reduced uptake may 
be present with a poor myocardial representation not allowing 
a reliable definition of the myocardial wall; although this method 
is less accurate and produces a lower H/M ratio respect to the one 
constructed on the myocardial mass, on the contrary it is more 
reproducible in patients with faint uptake, becoming therefore in 
our opinion the best approach for the evaluation of myocardial 
denervation, as early marker of PD and as differential param-
eter between PD and parkinsonims. In order to standardize the 
image analysis, the ROIs depiction is crucial: we try to use in all 
patients the same mediastinal ROI , of fixed dimensions. Moreover 
both ROIs are depicted on early images then pasted on delayed 
ones, being frequently the earlier uptake more favorable to define 
the ROI’s position. The procedure is particularly effective when 
the patient is repositioned in the same position in further controls. 
Irrespective of which procedure has been used, normal values for 
H/M range from 1.9 to 2.8 with a mean of approximately 2.2 [3, 4].
The H/M ratio reflects receptor density and integrity of 
pre-synaptic nerve terminals and uptake-1 function. A high ratio 
indicates a predominant localization of the tracer in the myocar-
dium that is expected for normal hearts, whereas a decreased ratio 
indicates a lower myocardial uptake, with an increased activity in 
extra-cardiac structures: therefore these data are in agreement with 
a reduced cardiac adrenergic receptor density [5].
The late H/M ratio combines information on neuronal function 
from uptake to release through the storage vesicles at the nerve 
terminals [6].
Sympathetic system in Parkinson’s disease 
Parkinson’s disease (PD) is the most common neurodegen-
erative parkinsonism characterized by the degeneration of both 
dopaminergic and non-dopaminergic neurons, with neuronal 
intra-cytoplasmic inclusions known as Lewy bodies. Patients with 
PD typically present tremor, rigidity and bradykinesia. Furthermore 
PD is characterized by a cardiac dysautonomia determined, 
as demonstrated in 1997 by Goldstein using cardiac imaging with 
18F-Dopamine, by the loss of at least one mechanism in post-gan-
glionic noradrenergic nerves [7]. After 15 years and many imaging 
studies performed with different techniques, the cardiac sympathetic 
denervation is today worldwide accepted as a PD biomarker [8–11]. 
Abnormalities of tau and α-synuclein have been described in 
a variety of neurodegenerative diseases, all showing parkinsonism 
with symptoms as tremor, bradykinesia, rigidity and gait impairment. 
Main tauopathies with parkinsonism are progressive supranuclear 
palsy (PSP) and cortico-basal degeneration (CBD). PSP is a clinical 
entity that shows supranuclear ophthalmoplegia, dystonia, rigidity of 
the neck and upper trunk, pseudobulbar palsy, and dementia [12]. 
CBD was first described in 1968 as cortico-dentato-nigral degenera-
tion with neuronal achromasia [13], which shows late middle age 
onset, progressive asymmetric rigidity, apraxia, tremor, and cortical 
and extrapyramidal dysfunction [14]. On the other hand, the main 
synucleinopathies with parkinsonism are Parkinson’s disease (PD) 
and multiple system atrophy with parkinsonism (MSA-P). PD is the 
most common cause of parkinsonism; MSA was first introduced 
in 1969 [15], and MSA-P has been recognized as a certain type of 
MSA showing predominant parkinsonism, autonomic failure, and 
poor levodopa-response [16].The clinical differentiation among 
PSP, CBD, MSA-P and PD is of decisive importance to pre-define 
the response to therapy and the respective prognosis. At disease 
onset, it is particularly difficult to precisely diagnose and distinguish 
these forms presenting with an akinetic-rigid syndrome. Further-
more PD is characterized by a variety of non-motor manifestations, 
which sometimes dominate the clinical picture and can precede 
the movement disorder, even by decades. These include constipa-
tion, depression, cognitive dysfunction, anosmia, REM behavior 
disorder, and orthostatic hypotension. The latter three non-motor 
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manifestations are associated with cardiac sympathetic denervation 
[17–19] (Figure 1A, B).
Almost all patients with PD have at least a partial olfactory 
dysfunction, and a substantial minority presents anosmia. Among 
patients with α-synuclein pathologies such as PD, the grade of 
anosmia measured by UPSIT scores, is positively correlated with 
myocardial noradrenergic innervation as assessed by cardiac sym-
pathetic neuroimaging [19]. REM behavior disorder (RBD) is a new 
pathological entity associated with PD. RBD patients present an evi-
dent myocardial noradrenergic denervation as demonstrated by 
cardiac sympathetic neuroimaging [21, 22]. Most PD patients may 
eventually develop dementia. In some patients dementia pre-
cedes the movement disorder or dominates the clinical picture, 
whereas the presence of visual hallucinations and fluctuating 
cognition leads to a diagnosis of Lewy Body Dementia (DLB) when 
in presence of insufficient signs in agreement with PD diagnosis. 
DLB is defined on the basis of a neuroimaging pattern concomitant 
with an evident cardiac sympathetic denervation. In this regard 
DLB differs from Alzheimer’s disease, in which cardiac sympa-
thetic innervation is generally intact. Because of this distinction, 
cardiac sympathetic neuroimaging has been proposed as a tool 
for a differential diagnosis of DLB respect to Alzheimers disease 
and Frontotemporal Dementia (FTD) [23, 24].
The sympathetic denervation in PD is further responsible for 
the orthostatic hypotension. This condition when in association with 
PD, is characterized by a cardiac and extra-cardiac noradrenergic 
denervation, accompanied by an arterial baroreflex failure, as re-
cently described by Goldstein [25].
The complexity of this scenario is further complicated, from 
the nuclear medicine point of view, by the ability of MRI to dif-
ferentiate various pathological entities that coexist in tau and 
α-synuclein abnormalities. Although new MRI techniques, as the 
thickness measurements of selected areas as well as functional 
analysis of the answers to specific motor tasks, have been recently 
introduced with interesting results [26–28], mIBG and dopamine 
imaging remain an important clinical tool, exclusively providing 
to the neurologist the functional status of a specifically involved 
neurotransmission. This scenario will be soon expanded by the 
availability of hybrid PET-MRI scanners, being also viable when PET 
and MRI may interact in a more strict connection [29].
The role of cardiac mIBG Imaging in PD
Being early differentiation of PD respect to other neurodegen-
erative parkinsonism crucial, there is an important need to improve 
the diagnostic accuracy of 123I-mIBG myocardial scintigraphy. 
This radionuclide study was originally developed to assess post-
ganglionic presynaptic cardiac sympathetic nerve endings in 
heart diseases for pathologies including congestive heart failure, 
ischemic heart disease, and cardiomyopathy. Subsequently, car-
diac uptake was demonstrated to be reduced in patients with Lewy 
body diseases, such as PD [30, 31] and DLB [32]; furthermore it 
has been reported to be useful for differentiating PD respect to 
other parkinsonism as well as DLB respect to Alzheimer’s disease 
(AD). Post mortem studies have shown that the number of cardiac 
tyrosine hydroxylase (TH)-immunoreactive axons, marker for sym-
pathetic axons, is decreased in pathologically confirmed PD and 
DLB [33, 34], supporting the findings of a reduced cardiac mIBG 
uptake in Lewy body diseases (Figure 2A, B).
Moreover it has been revealed that PD, DLB and pure auto-
nomic failure (PAF) share a single clinic-pathological entity: Lewy 
Bodies diseases (LBD) has thus become a general term for these 
conditions, Lewy bodies having been pathologically observed in the 
nervous system of patients affected with these disorders [35–38]. 
LBD present an impairment of adrenergic function and consequent-
ly an abnormal myocardial innervation imaging: the involvement of 
myocardial postganglionic sympathetic nerves may account for the 
reduction of myocardial mIBG uptake in patients with PD, as well 
as in patients with other LBD [39, 41]. Also patients with idiopathic 
RBD usually present a reduction of myocardial mIBG uptake; RBD 
consists of a wide range of neurodegenerative disorders, but the 
pathological entity of idiopathic RBD has not yet been confirmed.
In recent papers focusing the attention on diagnostic accuracy 
of cardiac mIBG for differentiating PD from Essential tremors, 
Figure 1. MIBG Cardiac imaging. Early (A) and Delayed (B). The H/M ratios were 1.55 and 1. 45, respectively. Patient was affected by early PD (Y&H 2)
 A  B
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as well as PD from other parkinsonism (MSA, PSP and CBD), dif-
ferent methodologies have been adopted, including acquisition 
parameters, processing, gold standard, and cut-off values. Two 
meta-analyses performed by Treglia [42] and Orimo [43] have 
calculated the diagnostic performances of mIBG in PD, MSA, PSP, 
CBD, LBD, also considering technical differences. 
Analyzing 11 studies published with the aim to distinguish PD 
from other parkinsonism including MSA, PSP and CBD, Orimo et 
al. [43] have observed a sensitivity ranging from 64.5% to 100% 
by using delayed H/M ratios, while specificities were between 
23.1% and 100.0%. In this meta-analysis, the pooled sensitivity and 
specificity were respectively 89.7% (95% CI: 81.6%, 94.5%) and 
82.6% (95% CI: 60.2%, 93.7%). The H/M early ratios in the same 
group of studies ranged from 67.5% to 92.0%, while the specifici-
ties were between 44.4% and 100.0%. In the evaluation of only 
5 studies including patients with PD at an early stage (Hoehn-Yahr 
stage 1 or 2) a sensitivity and specificity respectively of 94.1% 
and 80.2 has been calculated. Finally Orimo and colleagues have 
meta-analyzed the accuracy of mIBG in differentiating PD from MSA 
and PD from PSP. They have reported a 90% sensitivity and a 82% 
specificity from 10 studies focused on PD against MSA, while in 
PD versus PSP the sensitivity and specificity were 91,4% and 78% 
respectively. This meta-analysis demonstrated a pooled sensitivity 
of 89.7% and a specificity of 82.6% using the delayed H/M ratio 
for differentiating PD from other neurodegenerative parkinsonisms, 
supporting the use of the delayed ratio, although similar diagnostic 
performances have been obtained in this setting applying early H/M 
ratio. Similar mIBG performances were detected in PD at an early 
stage; although these data have been obtained at the present in 
a little series, they are in accordance with the hypothesis of mIBG 
as marker of pre-motor PD. It has to be pointed out that in PD 
myocardial mIBG’s uptake irreversibly and progressively decrease 
with disease’s progression; sometimes the cardiac denervation 
detected by mIBG precedes motor symptoms and is irrespective 
of dopamine loss in the striatum. These evidences enhance the 
mIBG impact in the clinical scenario of patients with PD. 
For differentiating PD from MSA, different meta-analysis [44, 
45] reported a sensitivity of 90% and a specificity of 85%. It has to 
be remembered that in MSA the central and preganglionic neu-
rons are pathologically involved whereas postganglionic sympa-
thetic neurons are usually spared. Therefore, as reduced cardiac 
mIBG uptake implies a decreased density of the post-ganglionic 
presynaptic cardiac sympathetic nerve endings, cardiac mIBG 
uptake is generally not reduced in MSA. However, a reduction of 
cardiac mIBG uptake was found in some patients with MSA [46, 
47]. Indeed, although the number of tyrosine hydroxylase-immu-
noreactive (TH-ir) axons of the heart is markedly decreased in PD 
and basically preserved in MSA [47, 48], 6 out of 15 subjects with 
longer duration of illness and with pathologically confirmed MSA 
exhibited a slightly decreased number of TH-ir axons [49]. This re-
sult suggests that a reduction of cardiac mIBG uptake can occur 
in MSA. Nevertheless, mIBG uptake in MSA patients tends to be 
normal or, when slightly decreased, with values generally higher 
than in PD (Figure 3A, B).
Similar mIBG performances in differentiating PD from PSP (sen-
sitivity: 91.4%; specificity: 78%) have been reported. As patients with 
PSP usually do not have autonomic dysfunction, thus cardiovascu-
lar autonomic dysfunction being an exclusionary feature of PSP, car-
diac mIBG uptake should not be reduced in PSP. Conversely, some 
patients with PSP showed reduced cardiac mIBG uptake probably 
due, at least in part, to the effects of tricyclic anti-depressants which 
may reduce cardiac mIBG uptake, non-suitably suspended before 
the radionuclide scan. Therefore, careful attention must be given 
to administered medications and to their suspension, to avoid 
pitfalls and mistakes .
Another recent meta-analysis performed by King [50] 
has confirmed the utility of mIBG scintigraphy in discriminating 
LBD from non-LBD: these authors have identified an ideal H/M 
threshold value (H/M = 1.77) that may be useful in differentiating 
these clusters. This threshold value has been obtained by a ROC 
analysis performed using H/M values of different studies; the 
H/M threshold value of 1.77 yielded 94% of sensitivity and 91% of 
Figure 2. MIBG Cardiac imaging. Early (A) and Delayed (B). The H/M ratios were 1.1 and 1.1. Patient was affected by LBD
 A  B
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specificity for the discrimination of LBD from non-LBD. Furthermore 
in this meta-analysis are reported the mean values of H/M ratio 
in controls (2.19), in PD (1.31), in MSA (2.13), in PSP (2.22), FTD 
(1.85), DLB (1.25) and RBD (1.32). These data demonstrated that 
DLB, PD and RBD are clustered around 1.2/1.3 of H/M ratio, clearly 
separated from MSA and PSP.
Another issue that may be addressed by mIBG is the evaluation 
of patients with freezing. Freezing is a form of gait disturbance with 
sudden and transient motor block. This condition may be a motor 
symptom of advanced PD as well as it can constitute the “Primary 
Progressive Freezing of Gait” (PPFG). Our group demonstrated 
a normal myocardial sympathetic activity in PPFG differently from 
patients with freezing and PD presenting severe reduction of mIBG 
uptake [51].
Limits in sensitivity and specificity 
Possible causes of false positive and false negative results of 
mIBG should be kept in mind. It should be noted that a decreased 
myocardial mIBG uptake is not specific of LBD and PD; in fact, vari-
ous heart diseases and diabetes may damage the postganglionic 
sympathetic neurons, leading to false-positive mIBG findings [52, 53]. 
In particular false-positive results may also be age-related and 
non-specific for postganglionic sympathetic degeneration, showing 
myocardial mIBG uptake a significant age-related decrease. 
False-negative results of mIBG scintigraphy in patients with PD 
may be caused by an early stage of disease, in presence of a dis-
ease duration less than one year, by tremor-dominant phenotypes, 
by some genetically determined PD [54].
Conclusion
Metaiodobenzylguanidine was developed initially as a tracer for 
oncological imaging [55, 56]; when labeled with 123I or 131I, it may 
detect apudomas, such as pheochromocytomas and paragan-
gliomas [57]. In the last years mIBG has found an important role 
also in neurology and cardiology, as cardiac innervation’s tracer 
[58]. Myocardial mIBG scintigraphy helps to differentiate between 
PD and other parkinsonian syndromes in clinically difficult cases. 
Furthermore, the myocardial mIBG scintigraphy allows insights into 
the pathophysiology of PD, significantly correlating with the motor 
phenotype and with the nigrostriatal function (measured by DATs-
can). These facts suggest that cerebral nigrostriatal dopaminergic 
degeneration and myocardial sympathetic degeneration coexist in 
PD. However new emerging data support the idea that dopamine 
and sympathetic involvement may not progress linearly in paral-
lel; sometimes mIBG’s cardiac uptake reduction precedes motor 
impairment and dopamine degeneration in PD patients. Finally the 
contemporary use of MIBG and DATscan permits to distinguish 
specific pathological entities with similar symptoms.
References
1. Bengel FM, Schwaiger M. Assessment of cardiac sympathetic neuronal 
function using PET imaging. J Nucl Cardiol 2004; 11: 603–616.
2. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine: Phar-
macology and clinical studies. Am J Physiol Imaging 1986; 1: 96–103.
3. Somsen GA, Verberne HJ, Fleury E, Righetti A. Normal values and 
within-subject variability of cardiac I-123 MIBG scintigraphy in healthy indi-
viduals: implications for clinical studies. J Nucl Cardiol 2004; 11: 126–133.
4. Jacobson AF, Senior R, Cerqueira MD et al. ADMIRE-HF Investigators. 
Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac 
events in heart failure. Results of the prospective ADMIRE-HF (AdreView 
Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll 
Cardiol 2010; 55: 2212–2221.
5. Patel AD, Iskandrian AE. MIBG imaging. J Nucl Cardiol 2002; 9: 75–94.
6. Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG 
scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging 2009; 
36: 555–559.
7. Goldstein DS, Holmes C, Cannon RO 3rd, Eisenhofer G, Kopin IJ. Sympa-
thetic cardioneuropathy in dysautonomias. N Engl J Med 1997; 336: 696–702.
8. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound 
cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 
2005; 15: 29–34.
Figure 3. MIBG Cardiac imaging. Early (A) and Delayed (B). The H/M ratios were 2.1 and 2.0. Patient was affected by Primary Idiopathic Freezing of Gait
 A  B
Nuclear Medicine Review 2013, Vol. 16, No. 1
www.nmr.viamedica.pl40
Review
9. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Taka-
hashi H. Degeneration of cardiac sympathetic nerve begins in the early 
disease process of Parkinson’’s disease. Brain Pathol 2007; 17: 24–30.
10. Arabia G, Novellino F, Morelli M et al. Mixed tremors with integrity of ni-
grostriatal system: a clinical and DAT-SPECT follow-up study. Mov Disord 
2010; 25: 662–664.
11. Novellino F, Arabia G, Bagnato A et al. Combined use of DAT-SPECT and 
cardiac MIBG scintigraphy in mixed tremors. Mov Disord 2009 15; 24: 
2242–2248.
12. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. 
Arch Neurol 1964; 10: 333–359.
13. Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration 
with neuronal achromasia. Arch Neurol 1968; 18: 20–33.
14. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship 
to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 
2003; 54: S15–S19.
15. Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sen-
sitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 
1969; 32: 28–34.
16. Gilman S, Wenning GK, Low PA. Second consensus statement on the 
diagnosis of multiple system atrophy. Neurology 2008; 71: 670–676.
17. Goldstein DS, Sewell L, Holmes C. Orthostatic hypotension from sympa-
thetic denervation in Parkinson’s disease. Neurology 2002; 58: 1247–1255.
18. Goldstein DS, Sewell L, Holmes C. Association of anosmia with autonomic 
failure in Parkinson disease. Neurology 2010; 74: 245–251.
19. Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more 
markedly in patients with REM sleep behavior disorder than in those with early 
stage Parkinson’s disease. Parkinsonism Relat Disord 2010; 16: 252–255. 
20. Goldstein DS, Holmes C, Bentho O et al. Biomarkers to detect central do-
pamine deficiency and distinguish Parkinson disease from multiple system 
atrophy. Parkinsonism Relat Disord 2008; 14: 600–607.
21. Paglionico S, Labate A, Salsone M et al. Involvement of cardiac sympathetic 
nerve endings in a patient with idiopathic RBD and intact nigrostriatal path-
way. Parkinsonism Relat Disord 2009; 15: 789–791.
22. Miyamoto T, Miyamoto M, Inoue Y, Usui Y, Suzuki K, Hirata K. Reduced 
cardiac 123I-MIBGscintigraphy in idiopathic REM sleep behavior disorder 
. Neurology 2006; 67: 2236–2238.
23. Yoshita M, Taki J, Yokoyama K et al. Value of 123I-MIBG radioactivity in the 
differential diagnosis of DLB from AD. Neurology 2006; 66: 1850–1854.
24. Novellino F, Bagnato A, Salsone M et al. Myocardial (123)I-MIBG scintigra-
phy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging 
2010; 31: 1903–1911.
25. Goldstein DS, Sewell L, Sharabi Y. Autonomic dysfunction in PD: a window 
to early detection? J Neurol Sci. 2011; 310: 118–122.
26. Morelli M, Arabia G, Salsone M et al. Accuracy of magnetic resonance 
parkinsonism index for differentiation of progressive supranuclear palsy from 
probable or possible Parkinson disease. Mov Disord 2011; 26: 527–533.
27. Cerasa A, Morelli M, Augimeri A et al. Prefrontal thickening in PD with 
levodopa-induced dyskinesias: New evidence from cortical thickness 
measurement. Parkinsonism Relat Disord 2012 Jun. [Epub ahead of print] 
PubMed PMID: 22742954.
28. Cerasa A, Pugliese P, Messina D et al. Prefrontal alterations in Parkinson’s 
disease with levodopa-induced dyskinesia during fMRI motor task. Mov 
Disord 2012; 27: 364–371.
29. Mansi L, Ciarmiello A, Cuccurullo V. PET/MRI and the revolution of the third 
eye. Eur J Nucl Med Mol Imaging 2012; 39: 1519–1524.
30. Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral 
degeneration and progressive supranuclear palsy using iodine-123 meta-io-
dobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155: 60–67.
31. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. 123I-meta-iodo-
benzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol 
Neurosurg Psychiatry 1999; 67: 189–194.
32. Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M. Cardiac 
123I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bod-
ies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 
2001; 70: 781–783.
33. Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T. Cardiac sympa-
thetic denervation precedes neuronal loss in the sympathetic ganglia in 
Lewy body disease. Acta Neuropathol 2005; 109: 583–588.
34. Amino T, Orimo S, Itoh Y, Takahashi A, Uchihara T, Mizusawa H. Profound 
cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 
2005; 15: 29–34.
35. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sym-
pathetic imaging in Lewy body diseases and related movement disorders. 
Q J Nucl Med Mol Imaging 2008; 52: 378–387.
36. Rascol O, Schelosky L. 123I-Metaiodobenzylguanidine scintigraphy in 
Parkinson’s disease and related disorders. Mov Disord 2009; 24: 732–741.
37. Treglia G, Cason E. Diagnostic performance of myocardial innervation imag-
ing using MIBG scintigraphy in differential diagnosis between dementia with 
Lewy bodies and other dementias: a systematic review and a meta-analysis. 
J Neuroimaging 2012; 22: 111–117.
38. Hishikawa N, Hashizume Y, Yoshida M, Sobue G. Clinical and neuropatholog-
ical correlates of Lewy body disease. Acta Neuropathol 2003; 105: 341–350.
39. Jost WH, Del Tredici K, Landvogt C, Braune S. Importance of 123I-metaio-
dobenzylguanidine scintigraphy/single photon emission computed tomo-
graphy for diagnosis and differential diagnostics of Parkinson syndromes. 
Neurodegener Dis 2010; 7: 341–347.
40. Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G. Recent develop-
ments in innervation imaging using iodine-123-metaiodobenzylguanidine 
scintigraphy in Lewy body diseases. Neurol Sci 2010; 31: 417–422.
41. Yamashina S, Yamazaki J Neuronal imaging using SPECT. Eur J Nucl Med 
Mol Imaging 2007; 34: 939–950.
42. Treglia G, Cason E, Stefanelli A et al. MIBG scintigraphy in differential diag-
nosis of Parkinsonism: a meta-analysis. Clin Auton Res. 2012; 22: 43–55.
43. Orimo S, Suzuki M, Inaba A, Mizusawa H. 123I-MIBG myocardial scintig-
raphy for differentiating Parkinson’s disease from other neurodegenerative 
parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat 
Disord 2012; 18: 494–500. 
44. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the 
differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 
11: 351–355.
45. Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ. Diffusion 
weighted imaging best discriminates PD from MSA-P: a comparison with tilt 
table testing and heart MIBG scintigraphy. Mov Disord 2007; 22: 1771–1776.
46. Fröhlich I, Pilloy W, Vaillant M, Diederich NJ. Myocardial MIBG scintigraphy: 
a useful clinical tool? A retrospective study in 50 parkinsonian patients. 
Neurol Sci 2010; 31: 403–406.
47. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability 
of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. 
J Neurol Neurosurg Psychiatry 2005; 76: 249–251.
48. Spiegel J, Hellwig D, Farmakis G et al. Myocardial sympathetic degenera-
tion correlates with clinical phenotype of Parkinson’s disease. Mov Disord 
2007; 22: 1004–1008.
49. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A. Degenera-
tion of cardiac sympathetic nerve can occur in multiple system atrophy. Acta 
Neuropathol 2007; 113: 81–86.
50. King AE, Mintz J, Royall DR. Meta-analysis of (123) I-MIBG cardiac scin-
tigraphy for the diagnosis of Lewy body- related disorders. Mov Disord 
2011; 26: 1218–1224.
51. Salsone M, Bagnato A, Novellino F et al. Cardiac MIBG scintigraphy in 
primary progressive freezing gait. Parkinsonism Relat Disord 2009; 15: 
365–369.
52. Kyuma M, Nakata T, Hashimoto A, Nagao K, Sasao H, Takahashi T. 
Incremental prognostic implications of brain natriuretic peptide, cardiac 
41www.nmr.viamedica.pl
Cascini Giuseppe Lucio et al., MIBG Neurological applications
Review
sympathetic nerve innervation, and non cardiac disorders in patients with 
heart failure. J Nucl Med 2004; 45: 155–163.
53. Gazzaruso C, Coppola A, Montalcini T et al. Lipoprotein(a) and homocyst-
eine as genetic risk factors for vascular and neuropathic diabetic foot in 
type 2 diabetes mellitus. Endocrine 2012; 41: 89–95.
54. Quattrone A, Bagnato A, Annesi G et al. Myocardial 123metaiodobenzylguan-
idine uptake in genetic Parkinson’s disease. Mov Disord 2008; 23: 21–27.
55. Cuccurullo V, Cascini G, Rossi A, Tamburrini O, Rotondo A, Mansi L. Patho-
physiological premises to radiotracers for bone metastases. Q J Nucl Med 
Mol Imaging 2011; 55: 353–373.
56. Mansi L, Moncayo R, Cuccurullo V, Dottorini ME, Rambaldi PF. Nuclear 
medicine in diagnosis, staging and follow-up of thyroid cancer. Q J Nucl 
Med Mol Imaging 2004; 48: 82–95.
57. Cuccurullo V, Mansi L. Toward tailored medicine (and beyond): the phaeo-
chromocytoma and paraganglioma model. Eur J Nucl Med Mol Imaging 
2012; 39: 1262–1265.
58. Teresińska A. Metaiodobenzylguanidine scintigraphy of cardiac sympathetic 
innervations. Nuclear Medicine Review 2012; 15: 61–70.
